03/27/2025
5:17 PM | Samsara BioCapital, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13D/A | |
03/14/2025
3:43 PM | Fanucci Marsha (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
11:15 PM | Syros Pharmaceuticals (Filer)
| Form EFFECT | |
03/11/2025
4:46 PM | Syros Pharmaceuticals (Subject)
WIRTH PETER (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/10/2025
3:27 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
Get the Latest News and Ratings for SYRS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
03/10/2025
3:29 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:31 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:20 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:20 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:20 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:21 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
03/10/2025
3:21 PM | Syros Pharmaceuticals (Filer)
| Form S-8 POS | |
02/14/2025
9:10 AM | Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
02/14/2025
7:41 AM | Deep Track Capital, LP (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
02/12/2025
8:41 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Syros Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
01/16/2025
3:49 PM | Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2025
3:01 PM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/30/2024
4:11 PM | AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/27/2024
3:02 PM | Flagship Pioneering Fund VII, L.P. (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/13/2024
3:17 PM | Flagship VentureLabs IV, LLC (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
2:01 PM | Syros Pharmaceuticals (Subject)
Young Richard A (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/06/2024
6:00 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/25/2024
4:59 PM | Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
4:22 PM | Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
4:42 PM | Roth David (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
5:00 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
4:20 PM | Stephens Kristin (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
3:45 PM | Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
3:18 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
11:08 AM | Chee Conley (Reporting)
Syros Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/18/2024
6:01 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
4:24 PM | Bain Capital Life Sciences Fund II, L.P. (Filed by)
Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/14/2024
4:28 PM | Avidity Partners Management LP (Filed by)
Syros Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/13/2024
6:00 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/04/2024
4:00 PM | Stephens Kristin (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
NVIDIA's Worst Nightmare? (Ad) $2 TRILLION Quantum Gold Rush
While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible. Click here to learn how to get the ticker symbol <<< |
11/04/2024
4:01 PM | Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/04/2024
4:01 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/04/2024
4:01 PM | Roth David (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/04/2024
4:01 PM | Simonian Nancy A (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/31/2024
5:49 AM | Syros Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/02/2024
4:00 PM | Quirk Gerald E (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
4:00 PM | Syros Pharmaceuticals (Issuer)
Young Richard A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
4:00 PM | AKKARAJU SRINIVAS (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
4:00 PM | Chee Conley (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
4:00 PM | Haas Jason (Reporting)
Syros Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
6:01 AM | Syros Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
MarketBeat All Access